2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein

OncologyMedicineHealth Policy
Written By Kerrington .

This week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein, a hematology/oncology fellow at Vanderbilt University Medical Center, on his new paper published in JAMA Network Open titled "Indication of Measures of Uncertainty for Statistical Significance in Abstracts of Published Oncology Trials: A Systematic Review and Meta-analysis".

Kerrington .
Previous

2.37 Careerism, Presenting Abstracts, Twitter and the K-Index, & Classical Hematology Chat
Next

2.35 BONUS! How to Keep Up with the New Information in Medicine